Post-CDK4/6 inhibitor therapy in HR+/HER2- advanced breast cancer: expanding options and persisting uncertainties.

Hollinger AM, Bill R

Open source

DOI: 10.37349/etat.2026.1002400
Published: 2026
Container: Exploration of targeted anti-tumor therapy
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.37349/etat.2026.1002400,
  title = {Post-CDK4/6 inhibitor therapy in HR+/HER2- advanced breast cancer: expanding options and persisting uncertainties.},
  author = {Hollinger AM and Bill R},
  year = {2026},
  journal = {Exploration of targeted anti-tumor therapy},
  doi = {10.37349/etat.2026.1002400},
  url = {https://doi.org/10.37349/etat.2026.1002400}
}

RIS

TY  - JOUR
TI  - Post-CDK4/6 inhibitor therapy in HR+/HER2- advanced breast cancer: expanding options and persisting uncertainties.
AU  - Hollinger AM
AU  - Bill R
PY  - 2026
JO  - Exploration of targeted anti-tumor therapy
DO  - 10.37349/etat.2026.1002400
UR  - https://doi.org/10.37349/etat.2026.1002400
ER  -

APA

AM, H., & R, B. (2026). Post-CDK4/6 inhibitor therapy in HR+/HER2- advanced breast cancer: expanding options and persisting uncertainties.. Exploration of targeted anti-tumor therapy. https://doi.org/10.37349/etat.2026.1002400

Source records

pubmed · retrieved 2026-09-26T00:39:34.430Z
europe-pmc · retrieved 2026-09-26T00:39:34.440Z
doaj · retrieved 2026-09-26T00:39:34.464Z